Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cytori Therapeutics Inc. (CYTX) Tumbles in Pre-market Hours After Pricing Public Offering

Cytori Therapeutics Inc. (NASDAQ:CYTX) tumbled by 36.05% to $1.10 on pre-market trading on April 11, after pricing a public offering of 8,600,000 shares of common stock at $1.10 per share. The company expects to raise approximately $9.5 million in gross proceeds.

The underwritten public offering grants a 45-day option for the underwriters to purchase up to 15% of additional shares of its common stock. The offering is expected to close on or about April 17.

The therapeutics company said it intends to use the net proceeds from the sale on working capital and general corporate purposes, including the funding of the HABEO and ATI-0918 development programs.

Maxim Group LLC is acting as sole book-running manager for the offering.

Cytori Therapeutics Inc. (NASDAQ:CYTX) is a company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions.


What Does The Smart Money Sentiment Say?

According to our data, none of the 742 elite funds we track owned any shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) at the end of Q4. However, Jim Simons of Renaissance Technologies established a new position when it bought 10,091 shares valued at $15,000 as of the end of December 2016. Meanwhile, Ken Griffin of Citadel investment Group established a new position when it bought 37,293 shares valued at $56,000.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

The Bottom Line

Cytori Therapeutics Inc. (NASDAQ:CYTX) tumbled by more than 36% in the pre-market hours on Tuesday, following the pricing of a public offering. The company expects to fetch gross proceeds of approximately $9.5 million in that offering.

Are you interested in biotech and pharmaceuticals? Here are 10 least competitive pharmacy schools in America.

Follow Plus Therapeutics Inc. (NASDAQ:PSTV)
Trade (NASDAQ:PSTV) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.